Podcasts about tki

In this update, we review the TKI program of Eyepoint Pharmaceuticals with Dr. Jay Duker, President and CEO.

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Its always nice to be invited in, especially if you get to leave with something for someone else who missed the invite.http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958https://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity"A few seconds Clip from :(I've Had) The Time of My Life (From "Dirty Dancing" Soundtrack)Bill Medley, Jennifer WarnesMakai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController •Become a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).Presenters:John Heymach, MD, PhDChair and ProfessorDepartment of Thoracic/Head and Neck Medical OncologyRuth Legett Jones Distinguished ChairMD Anderson Cancer CenterHouston, TexasSolange Peters, MD, PhD Professor and Director of Medical OncologyDepartment of OncologyUniversity Hospital of LausanneLausanne, SwitzerlandContent based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.Link to full program: https://bit.ly/3L1eksIGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

DFW's Morning News speaks with McKinney Mayor Bill Cox about progress at TKI.See omnystudio.com/listener for privacy information.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to highlight chronic lymphocytic leukemia (CLL) updates from the 2025 ASH Annual Meeting. Drs Armstrong and Tawagi noted that CLL is typically diagnosed in asymptomatic, elderly individuals presenting with lymphocytosis. A definitive diagnosis is established by confirming the clonality of circulating B lymphocytes via immunoglobulin light chain restriction on flow cytometry, they explained. Treatment initiation is reserved for active disease, which is indicated by B symptoms, progressive cytopenias, threatened organ function, or bulky disease such as splenomegaly, they said. They continued by reporting several prognostic features that denote poor outcomes. Current standard frontline regimens use covalent BTK inhibitors or time-limited targeted regimens that include venetoclax (Venclexta), often combined with an anti-CD20 monoclonal antibody, according to the experts. They added that TKI-based therapy is preferred for patients with high-risk features. The phase 3 BRUIN CLL-313 trial (NCT05023980) investigated pirtobrutinib (Jaypirca), a highly selective noncovalent BTK inhibitor, compared with bendamustine and rituximab (BR) in patients with treatment-naive CLL. The trial showed a significant improvement in progression-free survival with pirtobrutinib vs BR. Pirtobrutinib was also associated with a favorable safety profile, with modest rates of class-associated toxicities, including all-grade bleeding, arthralgia, and atrial fibrillation. Although pirtobrutinib showed superior efficacy in BRUIN CLL-313, the clinical interpretation of these data is complicated because BR is an outdated control arm compared with contemporary frontline standards, Armstrong and Tawagi emphasized. Furthermore, the requirement for indefinite therapy with BTK inhibitors is a sequencing challenge, particularly as pirtobrutinib is currently approved in the post-covalent BTK inhibitor setting, they continued. However, its favorable toxicity profile suggests potential utility in elderly patients with pre-existing cardiovascular comorbidities, they noted. Future studies are focused on comparing pirtobrutinib vs time-limited venetoclax and evaluating various triplet regimens, they concluded.

Up The river and into the town kinda with tangents...again...www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"A few seconds Clip from :(I've Had) The Time of My Life (From "Dirty Dancing" Soundtrack)Bill Medley, Jennifer WarnesMakai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

We chat more and discuss boats and barges and mealswww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes. After the break, the trio looks ahead to sustained TKI therapy via EYP-1901 (Duravyu, EyePoint Pharmaceuticals) by examining data from the DAVIO-2 study. Drs. Sridhar, Borkar, and Weng are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Borkar, and Weng for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases. We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines. Key topics included: • The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment • The impact of disease progression on treatment decisions • Side effect management and the importance of palliative care • The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers! #RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology

We are back with lots of OncoPharm updates: 1. The belantamab mafodotin REMS program details are available....and it's a lot. How will belantamab mafodin-regimens be used with the upcoming MAJESTIC-3 data of teclistamab-daratumumab? 2. The capecitabine label is updated and calls for pre-treatment DPYD testing 3. Daratumumab gets an FDA approval for high-risk smoldering myeloma based on the AQUILA study Critique of AQUILA: https://doi.org/10.1093/oncolo/oyaf216 4. A pertuzumab biosimilar (Poherdy) is approved 5. Epcoritamab nets regular approval and a new indication with lenalidomide/rituximab (RR) for Follicular Lymphoma 6. Ziftomenib, a new menin inhibitor, is approved for NPM1 relapsed/refractory AML 7. Sevabertinib, a new HER2 inhibiting TKI, is approved for ERBB2 mutated NSCLC, with evidence of activity in patients previously treated with HER2-antibody-drug conjugates 8. Expected FDA approvals for durvalumab + FLOT in preoperative gastric/GEJ cancer; neoadjuvant pembrolizumb + enforumab vedotin in bladder cancer (non-cisplatin eligible), and tarlatamab regular approval for small cell lung cancer 9. Happy Thanksgiving!

Using Downtime in Kintago and the cast just chattingwww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

We level our crew to 11th, and chat, plan for the future!www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

UROONCO RCC associate editor Assoc. Prof. Carlotta Palumbo (IT) talks with medical oncologist Dr. Pasquale Rescigno (GB) about his presentation supporting the 'yes' position in the debate at EMUC25: “Is single agent TKI (tyrosine kinase inhibitor) still an option in selected mRCC patients? This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

We level our crew to 11th, and chat, plan for the future!www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

The TKI Crew keeps their Fall Season Rolling Along w/ another smash episode! On Today's Pod TKI's  Tori Corsaro is joined by GK Coach Faith Kempfer to discuss  the coaching college program at TKI, collegiate goalkeepers and what is similar or not to the youth environment. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

A roof top battle that barely touches the roof!www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

The Party fight goes right out the window in this final tower boss fight!www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

The "Blue Man Crew" in Demonic form attacks! Wait What?www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Tom Kobza owns TKI CNC in Billings, Montana. He is an avid angler and skilled manufacturer in multiple disciplines including the fishing industry where he produces premium rod holders, forward sonar pole mount kits as well as shuttles to name a few. Tom joins the JMO Podcast for the second time to share insights into the design and creation of TKI's products as well as recap some of the great fishing he's done this season.TKI CNC - https://www.youtube.com/@tkicnc6255 www.tkicnc.com

A Whole lot of sneaking around, in Plate Mail!www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Find us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Dropping Called lighting clouds indoors leads to some Obscure effectsBuy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

In today's episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Drilon discussed the efficacy data and implications of the ARROS-1 trial, highlighted the unique mechanism of action of zidesamtinib, noted the high central nervous system (CNS) response rates and favorable safety profile associated with the agent, and emphasized the potential for zidesamtinib to become a standard first-line therapy in the NSCLC treatment paradigm, especially for patients with prior TKI resistance or CNS disease.

Fighting 2 Large Sized Alchemical Golems with reach is no easy feat!Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

“All of these TKIs [tyrosine kinase inhibitors] inhibit BCR-ABL1 in some way, shape, or form. When BCR-ABL1 is mutated, it has uncontrolled tyrosine kinase activity, leading to rapid cell proliferation. When we then inhibit that BCR-ABL1 that's been mutated, we disrupt this abnormal signaling pathway that drives CML [chronic myeloid leukemia] cell proliferation and survival, ultimately leading to decreased cancer cell growth, increased apoptosis or cell death, and potentially inducing a disease remission,” Samantha Maples, PharmD, BCOP, clinical pharmacy specialist supervisor for hematology and cellular therapy at Allegheny Health Network in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the BCR-ABL1 inhibitor drug class.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 5, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to the use of BCR-ABL1 inhibitors in the treatment of CML. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 322: Nursing Strategies to Reduce Readmission Rates for Patients With Cancer Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies ONS Voice articles: Adherence to Oral Anticancer Medication Combination Therapy Shows Promise for Chronic Myeloid Leukemia The Case of the Medication Modification The Case of the Safety Session ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum articles: Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors Other ONS resources: Biomarker Database Financial Toxicity Huddle Card Tyrosine Kinase Inhibitors Huddle Card Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library National Comprehensive Cancer Network National Comprehensive Cancer Network patient resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “The IRIS study led to the approval of the BCR-ABL1 and TKI, imatinib, for CML in 2001 and completely changed the landscape of CML treatment. Then came the second-generation BCR-ABL1 TKIs: dasatinib in 2006, quickly followed by nilotinib in 2007. Thereafter came our second-generation, bosutinib, and our first approved third-generation TKI, ponatinib, both in 2012, which was a huge milestone as ponatinib overcomes resistance to the T315 I mutation, which no previously approved TKIs worked against.” TS 2:16 “The newest approved TKI, asciminib, is an allosteric inhibitor that binds to a different pocket on the BCR-ABL kinase via allosteric binding to the ABL myristoyl pocket. It's what's called a STAMP inhibitor, where STAMP stands for ‘specifically targeting the ABL myristoyl pocket.' And while all the TKIs target the BCR-ABL1 binding site, they can also inhibit different off-target kinases. And these differences in off-target inhibition are responsible for some of the different toxicities we see among the TKIs.” TS 4:51 “As a class, common toxicities include nausea; vomiting; diarrhea; cardiac toxicities, including cardiac arrhythmias and congestive heart failure; metabolic abnormalities such as hypercholesterolemia and hypertriglyceridemia; nephrotoxicity; hepatic toxicity; hemorrhaging and bleeding; as well as cytopenia. Individually, some of these agents are more likely to cause certain side effects compared to others, and there are unique toxicities associated with certain TKIs.” TS 8:10 “We've moved to using preemptive loperamide [in our clinic] for the first three days of starting treatment, because it's really hard to get patients to continue to take a medication if they have such severe diarrhea that they end up in the hospital or they're unable to leave their house. A lot of times, we will proactively give patients antiemetics and loperamide to help with the nausea, vomiting, and diarrhea. And then we can back off to an as-needed basis once they've been established on treatment. We can also use medications to help manage long-term complications that can require supportive care, such as statin therapy for high cholesterol, levothyroxine for hypothyroidism, anticoagulants for any venous thromboembolism, and antihypertensive medications for managing any new or worsening high blood pressure.” TS 12:44 “We are continually seeing these agents expand their indications to different lines of therapy, as well as more TKIs being approved for acute lymphoblastic leukemia. For example, asciminib just got approved in the frontline setting within the last year, whereas previously it was only approved in relapsed refractory setting. Last year, imatinib was the first BCR-ABL1 TKI to come out with a commercially supplied suspension option as well, which is huge in the pediatric space and [for] our adult patients who are unable to swallow tablets for other clinical reasons.” TS 21:22 “There is more information being published on the safe discontinuation of these medications with treatment-free remissions, and more information is coming out about who would be eligible and who can have the option to stop these treatments instead of having a lifelong chronic condition requiring continuous treatment. We're seeing more patients in clinical practice be able to stop BCR-ABL1 treatment, which has been a great development in CML.” TS 25:29

Its time to rest and recupe, but in the middle of the tower?Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rohit & Rahul Gosain are joined by Dr. Joshua Sabari from the NYU Langone Cancer Center to discuss the exciting recent approval of Zongertinib, the first oral TKI for HER2-positive lung cancer. We dived deep into the prevalence of HER2 mutations in non-small cell lung cancer, the study design and findings from the Beamion LUNG-1 trial, and the implications of this new therapy in clinical practice. Dr. Sabari shared insights on the efficacy of Zongertinib, including impressive response rates and progression-free survival data, as well as its side effect profile compared to other treatments like trastuzumab deruxtecan (T-DXd). Key topics covered in this episode: •⁠  ⁠Overview of HER2 mutations in lung cancer •⁠  ⁠Study design and results of the Beamion LUNG-1 •⁠  ⁠Comparison of Zongertinib and T-DXd in treatment settings •⁠  ⁠Management of common side effects associated with Zongertinib •⁠  ⁠Future directions for HER2-targeted therapies Join us for this informative discussion as we explore the latest advancements in lung cancer treatment and what they mean for patients and clinicians alike. Don't forget to subscribe for more episodes on new approvals, side effect management, and practice-changing data in oncology! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/

Battle in the Amplitheater of Tennison Tower rages on!Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

A panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigms.

The party stalks and gets the jump on the tower...Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.

Deception, Diplomacy or Intimidation? Which is best for an Interrigation that bars violence...Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Lady Mialari Docur's school for girls has many interesting secrets...Buy Fantasy Grounds Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Please visit answersincme.com/KTK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancers discusses strategies for treatment of patients with colorectal cancer using tyrosine kinase inhibitors. Upon completion of this activity, participants should be better able to: Identify patients with metastatic colorectal cancer (mCRC) who are suitable for tyrosine kinase inhibitor (TKI) treatment; Outline practical, patient-centered strategies to maximize quality of life in patients receiving later-line TKI treatment for mCRC; and Review approaches to manage adverse events associated with later-line TKI treatment for mCRC.

Fighting tiger people spellcaSTERS TAKES A LITTLE FAITH?Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

2 Commoners cowering in a corner, concern our cunning party and turn out to be a little too clever until...Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

To Holy Damage Or Not to Holy Damage, Muros & Karom are out of the question.Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer. Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 3 of the 2025 ASCO Annual Meeting. Today's selection features studies addressing the treatment of advanced renal cell carcinoma and 2 studies exploring novel approaches in non-small cell lung cancer. My disclosures are available in the transcript of this episode. The first abstract is number 4505. This study, led by Dr. Toni Choueiri of the Dana-Farber Cancer Institute, describes the final analysis of the CheckMate 214 trial, which compared the combination of nivolumab and ipilimumab with sunitinib for the first-line treatment of advanced renal cell carcinoma. The ipi-nivo combination is approved for the frontline treatment of intermediate and poor-risk advanced renal cell carcinoma based on the primary analysis of the CheckMate 214 trial, which demonstrated a higher response rate and longer overall survival compared with sunitinib. Today's presentation provided the final safety and efficacy results for the trial with long-term follow-up of more than 9 years.  The intent-to-treat (ITT) population in this trial comprised 550 patients randomized to nivo and ipi versus 546 who received sunitinib. The final analysis showed sustained long-term benefit for the combination therapy. Patients given nivolumab plus ipi had a 29% reduction in the risk for death compared with sunitinib. For patients with intermediate or poor-risk disease, there was a 31% reduction in the risk of death.   The probability of remaining in response through 8 years was more than doubled with nivolumab plus ipilimumab versus sunitinib in the ITT population at 48% versus 19%, and in the intermediate and poor-risk population at 50% versus 23%. The other important observation is that patients with favorable-risk disease appeared to have a 20% reduction in the risk for death at 9 years and more durable responses. This suggests a possible delayed benefit for ipi and nivo in this group since these differences were not seen in the earlier analysis.   No new safety signals emerged with longer follow-up, and the results confirm the use of ipi and nivo as a standard front-line combination therapy in this disease. Since this combination has been in widespread use for some years, the results are not surprising although the subgroup analysis suggesting benefit in favorable-risk patients is likely to inform practice in the future.   Today's second abstract is number is 8506, which was presented by Dr. Tony Mok from the Chinese University of Hong Kong, describing results from the phase 3 HERTHENA-Lung02 trial. This trial compared the antibody-drug conjugate patritumab deruxtecan with platinum-based chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following a third-generation tyrosine kinase inhibitor (TKI).  Patritumab deruxtecan, also known as HER3-DXd, comprises a fully human anti-HER3 IgG3 monoclonal antibody conjugated to a topoisomerase 1 inhibitor payload, and showed activity in a previous phase 2 trial in patients relapsing after EGFR TKI and chemotherapy.   In this phase 3 study, this agent was compared with platinum-based chemotherapy in eligible patients with an EGFR-activating mutation who had previously received 1 or 2 EGFR TKIs, at least one of which was a third-generation drug, with relapse or progression after this therapy. Five hundred and eighty-six patients were enrolled, with progression-free survival as the primary endpoint.  The primary analysis showed a 9-month progression-free survival of 29% for the experimental arm compared with 19% for platinum-based chemotherapy, for a hazard ratio of 0.77 and a P value of 0.011. With higher progression-free survival rates at 6 months and 12 months, HER3-DXd also had a better objective response rate (35.2% versus 25.3%) compared with platinum-based chemotherapy (PBC), and HER3-DXd also extended intracranial progression-free survival compared with PBC in patients with brain metastases, with a hazard ratio of 0.75. Grade 3 or more treatment-related adverse events occurred in 73% of patients treated with HER3-DXd and 57% of patients who received PBC. HER3-DXd had a higher rate of grade or more 3 thrombocytopenia, and drug-related interstitial lung disease occurred in 5% of patients in the HER3-DXd arm.   The follow-up will need more time to mature since no overall survival data are currently available, but definitely an agent to watch with interest. Moving on to today's final abstract, 8500, was presented by Dr. Pasi Jänne from the Dana-Farber Cancer Institute, describing results from the phase 2 portion of the KRYSTAL-7 study. This study is exploring the use of a potent KRAS inhibitor, adagrasib, in combination with pembrolizumab in patients with advanced or metastatic KRASG12C- mutated non-small cell lung cancer.  Adagrasib has already received accelerated approval in the U.S. for previously treated locally advanced or metastatic NSCLC with a KRASG12C mutation. A previous report from the KRYSTAL-7 study demonstrated encouraging activity in combination with pembrolizumab in the frontline setting for this patient group who also had more than 50% expression of PD-L1. The presentation today described efficacy and safety data for this drug combination across all PD-L1 expression levels.  One hundred and forty-nine patients with a median age of 67 years were treated with the combination, 104 of whom had PD-L1 expression level results available, representing the so-called biomarker population in this trial. The overall response rate for the entire study population was 44%. In the biomarker population, the overall response rate ranged from 36% in those with less than 1% PD-L1 expression to 61% for those with more than 50% expression. For all patients, the median response duration was just over 26 months, and the median progression-free and overall survival rates were 11 and 18.3 months respectively.    For the biomarker population, the median progression-free and overall survival were highest in those patients with more than 50% PD-L1. No new safety issues emerged from this analysis; the most frequent toxicities were nausea, diarrhea, and increases in transaminases. Immune-related toxicities included pneumonitis, hypothyroidism, and hepatitis. These are important results and the results of the phase 3 portion of KRYSTAL-7, which compares first-line therapy with adagrasib plus pembro versus pembro alone in the KRASG12C mutated/PD-L1 more than 50% group, will be informative. For those patients with lower levels of PD-L1 expression, the authors suggest that the treatment escalation may be beneficial, possibly including the addition of chemotherapy.  That concludes today's report. Thanks for listening and I hope you will join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share how You can improve your handling of "Aerial Service" as a goalkeeper. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

After A Week Off (Thanks All For Sharing Your Well Wishes Regarding The Union Staff Member) We are back! The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share how You can become a better goalkeeper coach. Great listen for young coaches! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro explore some common misconceptions on goalkeepers and how we can change that narrative.   Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share some tips on how you can become a more well rounded goalkeeper and not just a shot stopper.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss whether goalkeepers really need to go "D1" and why environment is more important than division.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss the biggest "problems" with "modern goalkeepers", and how TKI's attempting to bring something different to the table.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss the TKI "Apprenticeship" program and the benefits for young goalkeepers to work in an academy environment on and off the field.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro introduce the new TKI GK Coaching Course and breakdown some misconceptions about TKI. Great listen for young players and parents!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises